83730-53-4
基本信息
L-丁硫氨酸亚砜亚胺
丁硫氨酸-亚砜亚胺/(2S)-2-氨基-4-(S-丁基磺酰胺基)丁酸
nsc326231
D-Buthionine Sulfoximine
L-BUTHIONINE-SULFOXIMINE
L-BUTHIONINESULPHOXIMINE
L-BUTHIONINE-[S,R]-SULFOXIME
Buthionine - sulfoxide iMine
L-BUTHIONINE-S,R-SULPHOXIMINE
L-BUTHIONINE-(S,R)-SULFOXIMINE
L-BUTHIONINE (R,S)-SULFOXIMINE
物理化学性质
| 熔点 | 224-228 °C (dec.) |
| 熔点 | 224-228 °C (dec.) |
| 沸点 | 382.3±52.0 °C(Predicted) |
| 密度 | 1.29 |
| 折射率 | 1.6300 (estimate) |
| 储存条件 | -20°C |
| 储存条件 | 2-8°C |
| 溶解度 | H2O: 50 mg/mL, clear, colorless to faintly yellow |
| 溶解度 | 在水中的溶解度50 mg/mL，澄清，无色至淡黄色 |
| 形态 | 细粉 |
| 颜色 | 白色 |
| BRN | 2367136 |
| 稳定性 | 溶液不稳定，必须现配现用。 |
| CAS 数据库 | 83730-53-4 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
| 危险品标志 | Xi |
| 危险类别码 | 36/37/38 |
| 安全说明 | 22-24/25 |
| WGK Germany | 3 |
| WGK Germany | 3 |
| RTECS号 | EK7713440 |
| F | 10 |
| 海关编码 | 29309090 |
应用领域
丁硫氨酸-亚砜亚胺价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/11/08 | 23552 | L-丁硫氨酸-(S，R)-亚砜亚胺 L-Buthionine-(S,R)-sulfoximine, 99%, Thermo Scientific Chemicals | 83730-53-4 | 1g | 3346元 |
| 2024/11/08 | 23552 | L-丁硫氨酸-(S，R)-亚砜亚胺 L-Buthionine-(S,R)-sulfoximine, 99%, Thermo Scientific Chemicals | 83730-53-4 | 5g | 12586元 |
| 2024/11/08 | S9728 | 丁硫氨酸-亚砜亚胺 BSO (L-Buthionine-(S,R)-sulfoximine) | 83730-53-4 | 5mg | 573.3元 |
常见问题列表
γ-glutamylcysteine synthetase.
L-Buthionine-(S,R)-sulfoximine (BSO: 50 μM) treatment for 48 hr results in a 95% decrease in ZAZ and M14 melanoma cell line GSH levels, and a 60% decrease in GST enzyme activity. GST-π protein and mRNA levels are significantly reduced in both cell lines. L-Buthionine-(S,R)-sulfoximine (BSO) induces oxidative stress in a cell by irreversibly inhibiting g-glutamylcysteine synthetase, an essential enzyme for the synthesis of glutathione (GSH).
The average number of eye-spots (mean±SEM) is 5.36±0.29 (n=46), 7.79±0.45 (n=34) and 8.78±0.61 (n=32) in untreated controls, 2 mM L-Buthionine-(S,R)-sulfoximine (BSO) and 20 mM BSO treated mice, respectively. The 2 mM BSO treatment results in ~30% more eye-spots, and the 20 mM treatment results in 40% more eye-spots compared with untreated mice. It is showed that BSO causes an elevated frequency of DNA deletions during mouse development. BSO treatment reduced GSH concentration in mouse fetuses by 55% and 70% at 2 mM and 20 mM BSO doses, respectively, compared to untreated mice. Co-treatment with 2 mM BSO and 20 mM NAC depleted GSH to a similar extent as 2 mM BSO, consistent with the function of BSO to inhibit the g-GCS enzyme indispensable for GSH synthesis. Like GSH, cysteine levels dropped following BSO treatment.